Daiichi Sankyo Invests In Japanese Cancer Vaccine Maker ImmunoFrontier
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo announced an agreement with Tokyo-based biotech venture firm ImmunoFrontier to develop cancer vaccine CHP-NY-ESO-1 for refractory esophageal tumors